The domain within your query sequence starts at position 1 and ends at position 151; the E-value for the Serglycin domain shown below is 9e-75.

MQVPVGSRLVLALAFVLVWGSSVQGYPARRARYQWVRCKPNGFFANCIEEKGPQFDLIDE
SNNIGPPMNNPVLMEGPSKDFISNYDDYGSGSGSGSGSGSGSGSGSGSGFLGDMEWEYQP
TDESNIVYFNYKPFDRILTEQNQDQPEDDFI

Serglycin

Serglycin
PFAM accession number:PF04360
Interpro abstract (IPR007455):

Serglycin was first identified as an intracellular proteoglycan expressed by hematopoietic cells. All inflammatory cells highly synthesize serglycin and store it in granules, where it interacts with numerous inflammatory mediators, such as proteases, chemokines, cytokines, and growth factors. Later serglycin was found to be expressed by various non-hematopoietic cell types, such as tumour cells. Serglycin promotes the aggressive phenotype of tumours and confers resistance against drugs and complement system attack [ (PUBMED:24455486) ].

Human serglycin consists of a small core protein containing eight serine/glycine repeats. Each serine of this repeat region is a potential GAG attachment site [ (PUBMED:20807648) ].

This is a PFAM domain. For full annotation and more information, please see the PFAM entry Serglycin